World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
143
Citations
104889
World Ranking
1474
National Ranking
859

George D. Demetri publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where George D. Demetri sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 685 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

George D. Demetri D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where George D. Demetri sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 143 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

George D. Demetri is affiliated with the Dana-Farber Cancer Institute in the United States. Their research focuses primarily on the fields of Medicine, with a particular emphasis on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Gastroenterology, and Pathology and Forensic Medicine.

Their scholarly work covers significant topics including Sarcoma Diagnosis and Treatment, Gastrointestinal Tumor Research and Treatment, COVID-19 and healthcare impacts, Vascular Tumors and Angiosarcomas, COVID-19 Clinical Research Studies, CAR-T cell therapy research, and Lymphoma Diagnosis and Treatment.

Frequent coauthors working alongside them include:

  • Suzanne George
  • Gregory M. Coté
  • Jason L. Hornick
  • Priscilla Merriam
  • Chandrajit P. Raut

George D. Demetri has published regularly in notable scientific venues such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • The Lancet Oncology
  • Nature Medicine

Among recent papers authored or coauthored by George D. Demetri are:

  • Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study, 2020, The Lancet Oncology
  • The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research, 2020, Nature Medicine
  • Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19, 2021, JAMA Oncology
  • Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer, 2022, JAMA Network Open
  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin, 2020, UNC Libraries

George D. Demetri received the distinction of being a Member of the Association of American Physicians. This recognition reflects their professional standing within the medical research community.

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

    Heikki Joensuu;Peter J. Roberts;Maarit Sarlomo-Rikala;Leif C. Andersson

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

    Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer

  • 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*

    Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Granulocyte colony-stimulating factor and its receptor.

    GD Demetri;JD Griffin

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

    George D. Demetri;Margaret Von Mehren;Cristina R. Antonescu;Ronald P. DeMatteo

  • KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

    Brian P. Rubin;Samuel Singer;Connie Tsao;Anette Duensing

  • Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

    Tammy F Chu;Tammy F Chu;Maria A Rupnick;Maria A Rupnick;Risto Kerkela;Susan M Dallabrida

Frequent Co-Authors

Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
Suzanne George
Suzanne George Harvard University
Robert G. Maki
Robert G. Maki University of Pennsylvania
Christopher D.M. Fletcher
Christopher D.M. Fletcher Brigham and Women's Hospital
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Chandrajit P. Raut
Chandrajit P. Raut Brigham and Women's Hospital
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Heikki Joensuu
Heikki Joensuu University of Helsinki
Paolo G. Casali
Paolo G. Casali University of Milan
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean attending traditional, on-campus programs. Today, aspiring healthcare professionals can choose online degrees tailored to their career goals and schedules. For those interested in healthcare administration, top online mha programs that are cahme accredited offer flexibility and respected accreditation, ensuring quality education for future leaders.

Nursing professionals seeking advancement can benefit from rn bsn online programs no clinicals, which allow registered nurses to earn their bachelor's degree without additional clinical requirements. This is ideal for working nurses balancing their studies with professional responsibilities.

If you are considering a terminal nursing degree, there are options for accelerated paths such as the shortest online dnp program for those who want to progress quickly. For greater flexibility and accessibility, online dnp programs can accommodate diverse backgrounds and schedules.

Exploring these online medical and healthcare degrees can provide new opportunities for career advancement while fitting your lifestyle and ambitions.

Best Scientists Citing George D. Demetri

Trending Scientists

Recently Published Articles